WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Options
Query Language
Stem
Sort by:
List Length
Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
238. (WO2005007699) HUMAN ANTIBODY MOLECULES FOR IL-13
Latest bibliographic data on file with the International Bureau   

Pub. No.: WO/2005/007699 International Application No.: PCT/GB2004/003059
Publication Date: 27.01.2005 International Filing Date: 15.07.2004
IPC:
C07K 16/24 (2006.01)
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
16
Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18
against material from animals or humans
24
against cytokines, lymphokines or interferons
Applicants: MONK, Phillip, David[GB/GB]; GB (UsOnly)
JERMUTUS, Lutz[DE/GB]; GB (UsOnly)
MINTER, Ralph, Raymond[GB/GB]; GB (UsOnly)
SHORROCK, Celia, Patricia[GB/GB]; GB (UsOnly)
CAMBRIDGE ANTIBODY TECHNOLOGY LIMITED[GB/GB]; Milstein Building Granta Park Cambridge Cambridgeshire CB1 6GH, GB (AllExceptUS)
Inventors: MONK, Phillip, David; GB
JERMUTUS, Lutz; GB
MINTER, Ralph, Raymond; GB
SHORROCK, Celia, Patricia; GB
Agent: WALTON, Sean ; Mewburn Ellis LLP York House 23 Kingsway London Greater London WC2B 6HP, GB
Priority Data:
0407315.131.03.2004GB
60/487,51215.07.2003US
60/558,21631.03.2004US
60/573,79124.05.2004US
Title (EN) HUMAN ANTIBODY MOLECULES FOR IL-13
(FR) MOLECULES D'ANTICORPS HUMAINS ANTI-IL13
Abstract:
(EN) Specific binding members, in particular human anti-IL-13 antibody molecules and especially those which neutralise IL-13 activity. Methods for using anti-IL-13 antibody molecules in diagnosis or treatment of IL-13 related disorders, including asthma, atopic dermatitis, allergic rhinitis, fibrosis, inflammatory bowel disease and Hodgkin's lymphoma.
(FR) L'invention concerne des éléments de liaison spécifiques, en particulier des molécules d'anticorps anti-IL-13, et notamment ceux neutralisant l'activité de l'IL-13. L'invention concerne également des procédés d'utilisation des molécules d'anticorps anti-IL13 pour le diagnostic ou le traitement de troubles associés à l'IL-13, comprenant l'asthme, la dermatite atopique, la rhinite allergique, la fibrose, la maladie intestinale inflammatoire et le lymphome Hodgkinien.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (EPO) (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)